Apple Inc. (NASDAQ:AAPL) Declares iPhone 8 Is Still Months Away, But Leaks Are In Abundance
Apple Inc. (NASDAQ:AAPL) stock moved down -2.00% to the trading price of $140.31. Apple’s (AAPL) declared that iPhone 8 is still months away, but leaks are in abundance. The latest one reiterates claims of delay in availability of the iPhone 8, and claims that it won’t go on sale at the same time as the alleged iPhone 7s and iPhone 7s Plus. Furthermore, there is a sketch of the iPhone 8 doing the rounds revealing design details of the device.
CNBC got hold of a report from Drexel Hamilton analyst Brian White that reiterates the same claim of iPhone 8 delays as declared previously. The report says that the delay is mostly due to difficulties related to the new 3D sensing technology. White also claims that the device, though delayed, will arrive before the holiday season. Finally, the report also reiterates that the 5.8-inch iPhone 8 will be the only model to sport an OLED display. Its 52-week range quite noticeable, lower range was $59.14% and hit highest level of $-3.56%. The overall volume in the last trading session was 9.33 Million shares. The firm shares 50 day moving average was calculated 2.01%.
Shares of Merck & Co., Inc. (NYSE:MRK) held volume of 1.72 Million shares as compare to its average volume of 10281.49 shares. Merck (MRK) reported that Dr. John H. Noseworthy, president and CEO of Mayo Clinic, has been nominated to stand for election to the company’s board of directors. The annual election of Dr. Noseworthy and the other directors will take place in connection with Merck’s Annual Meeting of Shareholders on May 23, 2017. With the proposed addition of Dr. Noseworthy, and the planned retirement of C. Robert Kidder, the Merck board will include 13 members.
Chairman and CEO, Merck, Kenneth C. Frazier stated that they are pleased to nominate Dr. John Noseworthy to stand for election to the Merck board and look forward to benefiting from his first-hand insights about patient care and health care delivery as a leader of one of the largest non-profit health systems in the United States.
Dr. John H. Noseworthy is president and chief executive officer of Mayo Clinic, a not-for-profit organization operating in five states that is dedicated to medical care, research and education. Prior to his current appointment, he served as chair of Mayo Clinic’s Department of Neurology, medical director of the Department of Development, and vice chair of the Mayo Clinic Rochester Executive Board. Dr. Noseworthy is a professor in the Department of Neurology and served as editor-in-chief for Neurology, the official journal of the American Academy of Neurology. The stock traded at $62.52 by decreasing -0.06%. The firm has price to sales ratio of 4.32 and its price to book per share was 4.30.
Bristol-Myers Squibb Company (NYSE:BMY) traded at $53.27 by plunging -0.15% with share volume of 1.04 Million that was surprisingly higher than its average volume of 13481.12 shares. Britain’s healthcare cost-effectiveness watchdog NICE declared on Tuesday that Bristol-Myers Squibb’s immunotherapy drug Opdivo was not worth using on the state health service for treating head and neck cancer due to its high price.
The draft decision from the National Institute for Health and Care Excellence (NICE) is the latest example of an expensive new cancer drug being spurned by the watchdog over cost issues. Paul Workman, Chief Executive of the Institute of Cancer Research, said the decision would deny patients “a genuine breakthrough treatment” and he urged NICE and Bristol to work together to reach contract on price. Opdivo is also authorized to treat a number of other cancers.
Britain has led the way in measuring drug cost-effectiveness in a rational and dispassionate way, following the establishment of NICE nearly two decades ago, but the system is now facing increasing financial strains. The share is moved forward to its percent change from 52-week low of 16.55% and hanging back from its percent change from 52-week high of -29.52%.